RNAC
Income statement / Annual
Last year (2025), Cartesian Therapeutics Inc's total revenue was $2.80 M,
a decrease of 92.81% from the previous year.
In 2025, Cartesian Therapeutics Inc's net income was -$130.30 M.
See Cartesian Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.80 M |
$38.91 M |
$26.00 M |
$110.78 M |
$85.08 M |
$16.60 M |
$6.68 M |
$903.00 K |
$207.00 K |
$8.08 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.80 M
|
$38.91 M
|
$26.00 M
|
$108.74 M
|
$85.08 M
|
$16.60 M
|
$6.68 M
|
$903.00 K
|
$207.00 K
|
$8.08 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
0.98
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$58.03 M
|
$45.11 M
|
$71.26 M
|
$72.38 M
|
$68.74 M
|
$54.51 M
|
$42.74 M
|
$47.69 M
|
$45.17 M
|
$29.70 M
|
| General & Administrative Expenses |
$31.47 M
|
$30.13 M
|
$40.45 M
|
$23.86 M
|
$20.94 M
|
$18.91 M
|
$16.39 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$31.47 M
|
$30.13 M
|
$40.45 M
|
$23.86 M
|
$20.94 M
|
$18.91 M
|
$16.39 M
|
$17.26 M
|
$18.08 M
|
$12.25 M
|
| Other Expenses |
$0.00
|
$7.58 M
|
$710.00 K
|
-$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$89.50 M
|
$82.81 M
|
$112.42 M
|
$94.20 M
|
$89.67 M
|
$73.42 M
|
$59.13 M
|
$64.95 M
|
$63.24 M
|
$41.95 M
|
| Cost And Expenses |
$89.50 M
|
$82.81 M
|
$112.42 M
|
$96.24 M
|
$89.67 M
|
$73.42 M
|
$59.13 M
|
$65.93 M
|
$63.99 M
|
$42.75 M
|
| Interest Income |
$6.58 M
|
$7.39 M
|
$4.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.83 M
|
$3.03 M
|
$2.84 M
|
$1.56 M
|
$1.52 M
|
$1.49 M
|
$1.21 M
|
$1.25 M
|
| Depreciation & Amortization |
$0.00
|
$1.15 M
|
$843.00 K
|
$2.04 M
|
$1.72 M
|
$1.73 M
|
$2.03 M
|
$975.00 K
|
$750.00 K
|
$802.00 K
|
| EBITDA |
-$86.71 M |
-$75.99 M |
-$235.03 M |
$39.84 M |
-$5.16 M |
-$65.59 M |
-$51.80 M |
-$62.87 M |
-$63.37 M |
-$34.16 M |
| EBITDA Ratio |
-31
|
-1.95
|
-9.04
|
0.36
|
-0.06
|
-3.95
|
-7.76
|
-69.62
|
-306.11
|
-4.23
|
| Operating Income Ratio |
-31
|
-1.13
|
-3.32
|
0.13
|
-0.05
|
-3.42
|
-7.86
|
-72.01
|
-308.14
|
-4.29
|
| Total Other Income/Expenses Net |
-$52.79 M
|
-$33.24 M
|
-$152.29 M
|
$20.23 M
|
-$5.12 M
|
-$12.06 M
|
-$2.90 M
|
-$314.00 K
|
-$1.54 M
|
-$1.54 M
|
| Income Before Tax |
-$139.50 M
|
-$77.14 M
|
-$238.71 M
|
$34.77 M
|
-$9.72 M
|
-$68.88 M
|
-$55.35 M
|
-$65.34 M
|
-$65.32 M
|
-$36.21 M
|
| Income Before Tax Ratio |
-49.87
|
-1.98
|
-9.18
|
0.31
|
-0.11
|
-4.15
|
-8.29
|
-72.35
|
-315.56
|
-4.48
|
| Income Tax Expense |
-$9.19 M
|
$287.00 K
|
-$19.00 M
|
-$609.00 K
|
$15.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$130.30 M
|
-$77.42 M
|
-$219.71 M
|
$35.38 M
|
-$25.69 M
|
-$68.88 M
|
-$55.35 M
|
-$65.34 M
|
-$65.32 M
|
-$36.21 M
|
| Net Income Ratio |
-46.59
|
-1.99
|
-8.45
|
0.32
|
-0.3
|
-4.15
|
-8.29
|
-72.35
|
-315.56
|
-4.48
|
| EPS |
-5.02 |
-2.99 |
-49.76 |
7.33 |
-6.74 |
-20.42 |
-36.46 |
-87.55 |
-95.94 |
-103.52 |
| EPS Diluted |
-5.02 |
-3.29 |
-49.76 |
3 |
-6.6 |
-20.42 |
-36.46 |
-87.55 |
-95.94 |
-103.52 |
| Weighted Average Shares Out |
$25.97 M
|
$25.91 M
|
$5.17 M
|
$4.02 M
|
$3.18 M
|
$2.81 M
|
$1.27 M
|
$621.92 K
|
$567.36 K
|
$291.50 K
|
| Weighted Average Shares Out Diluted |
$25.97 M
|
$23.69 M
|
$5.17 M
|
$4.05 M
|
$3.18 M
|
$2.81 M
|
$1.27 M
|
$621.92 K
|
$567.36 K
|
$291.50 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
